Table 1 Baseline characteristics and home medication, according to the development of severe disease and vital status at discharge.

From: Prognosis of COVID-19 pneumonia can be early predicted combining Age-adjusted Charlson Comorbidity Index, CRB score and baseline oxygen saturation

Variables

Disease severity

Vital status at discharge

Moderate

Severe

p-value

Alive

Dead

p-value

n: 288

n: 104

n: 340

n: 52

Demographics

Gender (masculine)

159 (55)

71 (68)

0.020

196 (58)

34 (65)

0.291

Age (mean ± SD) (n: 392)

57 ± 16

71 ± 12

 < 0.001

59 ± 15

75 ± 11

 < 0.001

Comorbidities

Chronic lung disease (n: 233)

40 (28)

32 (36)

0.222

48 (26)

24 (52)

 < 0.001

Chronic heart disease (n: 371)

23 (9)

33 (32)

 < 0.001

35 (11)

21 (40)

 < 0.001

Arterial Hypertension (n: 392)

107 (37)

72 (69)

 < 0.001

138 (41)

41 (79)

 < 0.001

Obesity (n: 204)

18 (13)

19 (30)

0.003

24 (14)

13 (41)

 < 0.001

Diabetes mellitus (n: 375)

34 (12)

34 (36)

 < 0.001

51 (16)

17 (34)

0.002

Chronic kidney disease (n: 392)

10 (3)

13 (13)

0.001

12 (4)

11 (21)

 < 0.001

Cerebrovascular disease (n: 389)

15 (36)

27 (64)

 < 0.001

25 (7)

17 (33)

 < 0.001

Connective tissue disease (n: 383)

6 (2)

2 (2)

0.969

6 (2)

2 (4)

0.325

Chronic liver disease (n: 385)

8 (3)

7 (7)

0.075

10 (3)

5 (10)

0.019

Cancer (n: 389)

23 (8)

12 (12)

0.290

27 (8)

8 (15)

0.083

Immunodepression (n: 379)

13 (5)

7 (7)

0.306

13 (4)

7 (14)

0.002

Age-Charlson score, median (IQR) (n: 392)

2 (0–3.5)

4.5 (3–6.5)

 < 0.001

2 (1–4)

6.5 (4.7–7.5)

 < 0.001

Dependency activities of daily living (n: 383)

26 (9)

27 (28)

 < 0.001

30 (9)

23 (46)

 < 0.001

Home medications

Antiplatelets (n: 380)

38 (13)

31 (33)

 < 0.001

48 (14)

21 (44)

 < 0.001

Anticoagulants (n: 382)

11 (4)

16 (16)

 < 0.001

16 (5)

11 (22)

 < 0.001

ARA-II or ACE inhibitors (n: 386)

85 (30)

58 (59)

 < 0.001

109 (33)

34 (67)

 < 0.001

Beta blockers (n: 385)

25 (9)

24 (24)

0,570

33 (10)

16 (31)

0,096

Vitamin D supplements (n: 381)

14 (5)

6 (6)

 < 0.001

15 (5)

5 (10)

 < 0.001

  1. ARA: angiotensin II receptor antagonists. ACEi: angiotensin-converting enzyme inhibitor. In each variable, total number of valid data is specified in the first column. In each outcome, absolute frequency, percentage by outcome and p-values for the comparation of moderate vs severe disease and alive vs dead at discharge are shown.
  2. In bold and italic those associations that are statistically significant.
  3. IQR: interquartile range; SD: standard deviation.
Back to article page